<DOC>
	<DOC>NCT01998828</DOC>
	<brief_summary>This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.</brief_summary>
	<brief_title>Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia, Essential</mesh_term>
	<criteria>Diagnosis of either PV or ET as defined by the 2008 World Health Organization (WHO) Diagnostic Criteria Requires treatment for PV or ET, in the opinion of the study investigator Intolerant of, resistant to, or refuses current or available treatment for PV or ET Direct bilirubin ≤ 2.0 x upper limit of the normal range (ULN) Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN Calculated creatinine clearance (CrCl) of ≥ 45 mL/min Life expectancy &gt; 24 weeks Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception Females who are nursing must agree to discontinue nursing before the first dose of study drug Able to comprehend and willing to sign informed consent form Prior splenectomy Uncontrolled intercurrent illness, per protocol Known positive status for human immunodeficiency virus (HIV) Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier Myeloproliferative neoplasmdirected therapy, other than aspirin, hydroxyurea, anagrelide, and/or phlebotomy, within 21 days prior to the first dose of study drug Anagrelide within 7 days prior to the first dose of study drug Presence of peripheral neuropathy ≥ Grade 2 Unwilling or unable to take oral medication Prior use of a JAK1 or JAK2 inhibitor Use of strong CYP3A4 inducers within 1 week prior to the first dose of study drug QTc interval &gt; 450 msec, unless attributed to bundle branch block</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Polycythemia</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>Thrombocytosis</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
</DOC>